LONDON: ECO Animal Health Group plc (AIM: EAH), a fast-growing global animal health company, posted resilient financial results for the year ended 31 March 2025, underscoring the success of its regional growth strategy, disciplined cost control, and continued advancement of its proprietary R&D pipeline.
Group sales reached £79.6 million, down from £89.4 million a year earlier, yet in line with revised expectations after a strong second half. Gross margin improved to 45%, driven by geographic mix and pricing discipline, while adjusted EBITDA totaled £7.3 million. Earnings per share surged 61% to 2.49p, and profit before tax rose to £4.0 million from £3.0 million.
North America was a key performance driver, with revenue growing 16% and contributing a larger share to group results. China showed late momentum, finishing 3% ahead of the previous year on a constant currency basis, while South East Asia demonstrated recovery through a strengthened order book.
CEO David Hallas said, “We’re pleased to report another robust year, achieved despite macroeconomic and market challenges. Our pricing strategies, product mix, and disciplined spending led to stronger margins and sustained cash flow.”
R&D spend increased to £8.6 million, with significant progress across the development pipeline. Regulatory submission for ECOVAXXIN® MS, a mycoplasma poultry vaccine, was filed with EMA, with further filings planned over the next 12 months. Up to nine products are expected to be approved in the U.S. and EU in the next five to six years.
Post-year end, ECO launched a share buy-back program and reported stronger-than-budgeted revenue from China and the U.S. The company remains focused on executing its pipeline-driven growth strategy and positioning itself as a global leader in sustainable animal health.